NextCure (NXTC) Income towards Parent Company (2018 - 2026)
NextCure (NXTC) posted quarterly Income towards Parent Company of -$15.9 million for Q1 2026, down 33.2% year-over-year from -$23.7 million in Q1 2025, and down 62.42% quarter-over-quarter from -$9.8 million in Q4 2025.
NextCure (NXTC) Income towards Parent Company (2018 - 2026) Analysis & Trends
NextCure's Income towards Parent Company history runs 9 years deep, the most recent figure standing at -$15.9 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 33.2% year-over-year to -$15.9 million; the TTM figure through Mar 2026 stood at -$74.9 million (down 18.04% YoY), while the FY2025 annual figure was -$189.5 million, down 8.39% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$15.9 million, down from -$9.8 million in the prior quarter.
- The five-year high for Income towards Parent Company was -$9.8 million in Q4 2025, with the low at -$34.0 million in Q2 2025.
- The 5-year median for Income towards Parent Company is -$17.7 million (2022), against an average of -$19.2 million.
- The sharpest annual moves came in 2024 and 2025: Income towards Parent Company jumped 42.58% in 2024, then slumped 40.28% in 2025.
- NextCure's Income towards Parent Company stood at -$17.7 million in 2022, then advanced by 12.84% to -$15.4 million in 2023, then advanced by 12.03% to -$13.6 million in 2024, then increased by 28.03% to -$9.8 million in 2025, then sank by 62.42% to -$15.9 million in 2026.
- Business Quant data shows NXTC's Income towards Parent Company at -$15.9 million in Q1 2026, -$9.8 million in Q4 2025, and -$15.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.47 Mn |
| Mar 31, 2026 | -15.87 Mn |
| Dec 31, 2025 | -9.77 Mn |
| Sep 30, 2025 | -15.30 Mn |
| Jun 30, 2025 | -33.98 Mn |
| Mar 31, 2025 | -11.91 Mn |
| Dec 31, 2024 | -13.57 Mn |
| Sep 30, 2024 | -13.76 Mn |
| Jun 30, 2024 | -24.23 Mn |
| Mar 31, 2024 | -18.54 Mn |
| Dec 31, 2023 | -15.43 Mn |
| Sep 30, 2023 | -23.96 Mn |
| Jun 30, 2023 | -28.20 Mn |
| Mar 31, 2023 | -16.63 Mn |
| Dec 31, 2022 | -17.70 Mn |
| Sep 30, 2022 | -21.69 Mn |
| Jun 30, 2022 | -20.61 Mn |
| Mar 31, 2022 | -24.51 Mn |
| Dec 31, 2021 | -17.63 Mn |
| Sep 30, 2021 | -22.05 Mn |